WATERTOWN, Mass., October 4, 2006 – EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced it has secured $24 million in Series C financing led by existing investor Fidelity Biosciences.The company also said that Jean Marie Vallet, Ph.D. has joined its management team as vice president of Business to joining EnVivo, Dr. Vallet was vice president of Business Development.
